Back
Speaker illustration

Professor Hiddo Heerspink

University Medical Center Groningen, Groningen (Netherlands (The))

Presentations

Q&A - Challenging paradigms and changing the course of chronic kidney disease the era of SGLT2i.

Event: ESC Asia with APSC & AFC 2020

Topic: Renal Failure and Cardiovascular Disease

Session: Challenging paradigms and changing the course of chronic kidney disease (CKD) The era of SGLT2i

Access
0
Thumbnail

Challenging paradigms and changing the course of chronic kidney disease the era of SGLT2i.

Event: ESC Asia with APSC & AFC 2020

Topic: Renal Failure and Cardiovascular Disease

Session: Challenging paradigms and changing the course of chronic kidney disease (CKD) The era of SGLT2i

Access
0
Thumbnail

What are the mechanisms linking novel antidiabetic treatments to cardiovascular benefit?

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Diabetes and the Heart

Session: Balancing Treatment Needs for Diabetic Patients with Cardiovascular Disease

Access
0
Thumbnail

Natriuretic effect of 2 weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function: results of the DAPASALT trial

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Antidiabetic Pharmacotherapy

Session: Improving Cardiovascular Function and Clinical Outcome in Diabetes Using New Guideline-Based Pharmacotherapy

Access
0
Thumbnail

DAPA-CKD - Dapagliflozin in Patients with Chronic Kidney Disease

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Renal Failure and Cardiovascular Disease

Session: Hot Line DAPA-CKD

Access
0
Thumbnail

Hot Line DAPA-CKD.

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Renal Failure and Cardiovascular Disease

Session: Hot Line DAPA-CKD

Access
0
Thumbnail

This platform is supported by

logo Novo Nordisk